Vical To Retain Marketing Rights To Allovection-7 In Deal With AnGes
This article was originally published in The Pink Sheet Daily
Executive Summary
AnGes gains Japanese rights to the cancer biologic as part of the $100 mil. agreement.
You may also be interested in...
Vical Shifts To Infectious Disease After Allovectin Fails In Melanoma
CEO Vijay Samant defends Vical’s DNA-based technology platform after 20 years of development culminates in Phase III failure. But the platform still shows promise in other therapeutic areas, Vical says as the company absorbs a major blow to stock price.
Cash-Strong Vical Narrows Focus To Two Lead Programs
Wary of current financial environment, biotech is bullish on early pipeline projects but will await partners to advance them.
Cash-Strong Vical Narrows Focus To Two Lead Programs
Wary of current financial environment, biotech is bullish on early pipeline projects but will await partners to advance them.